ZimVie is a pure-play dental medical device company focused on tooth replacement and restoration, following the sale of its spine segment in April 2024. ZimVie sells three complementary product lines: dental implants, biomaterials, and digital dentistry solutions. Dental implants — titanium systems including the premium TSX and T3 PRO products — are the largest category at roughly 60% of revenue, sold to oral surgeons, dental specialists, general dentists, and dental service organizations. Biomaterials, including bone grafts and barrier membranes, are used to prepare patients for implant surgery. Digital dentistry solutions include the RealGUIDE surgical planning software, 3D-printed surgical guides, and the Implant Concierge outsourced treatment planning service, as well as distributed intraoral scanners. ZimVie sells primarily through a direct sales force across roughly 50 countries, with the U.S. accounting for approximately 60% of revenue. The implant and biomaterials businesses are transactional and tied to procedure volumes, while digital products carry a more recurring revenue profile. ZimVie's growth strategy centers on the dental implant market being underpenetrated — management estimates only about 25% of edentulous patients receive implants — and positions digital workflow tools as the key lever to expand adoption among less experienced clinicians. ZimVie also runs dental training institutes in Florida, California, and Switzerland, which serve as a commercial funnel for driving implant and digital tool adoption. Manufacturing cost reduction, including shifting production to its lower-cost Valencia, Spain facility, has been a source of margin improvement.